VK2735

Phase 3Recruiting
0 views this week 0 watching Active
Interest: 44/100
44
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Weight Loss

Conditions

Weight Loss

Trial Timeline

Jun 23, 2025 → Aug 1, 2027

About VK2735

VK2735 is a phase 3 stage product being developed by Viking Therapeutics for Weight Loss. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07104383. Target conditions include Weight Loss.

What happened to similar drugs?

4 of 20 similar drugs in Weight Loss were approved

Approved (4) Terminated (1) Active (15)
Exenatide + PlaceboEli LillyApproved
olanzapineEli LillyApproved
AripiprazoleBristol Myers SquibbApproved
🔄VK2735Viking TherapeuticsPhase 3
🔄Eloralintide + PlaceboEli LillyPhase 3
🔄Eloralintide + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07104383Phase 3Recruiting
NCT07104500Phase 3Active

Competing Products

20 competing products in Weight Loss

See all competitors